Statement: T1 N0 M0 patients are eligible for the primary trial. bone marrow lymphoplasmacytic infiltrate is a morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in a bone marrow specimen.
Primary_evidence: DISEASE CHARACTERISTICS:   Histologically confirmed stage I, II, or III breast cancer   T1-3, N0-2, M0   Patients with sentinel node biopsy positive disease must have undergone axillary dissection   Tumor must be confined to the breast without detected metastases elsewhere   T4 disease with minimal dermal invasion allowed   No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer   No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite breast that has not been proven benign   No distant metastases   No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or CT   Must have undergone prior total mastectomy OR breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with negative margins) with radiotherapy planned   Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery   Negative surgical margins   Axillary clearance with at least 6 lymph nodes examined OR negative sentinel node biopsy   Known HER2 status by immunohistochemistry or fluorescence in situ hybridization   Hormone receptor status:   Estrogen and progesterone receptor negative   Less than 10% positive tumor cells by immunohistochemistry   PATIENT CHARACTERISTICS:   Age: Not specified   Sex:   Not specified   Menopausal status:   Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR   Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since LMP without prior hysterectomy (OR age 50 and over) Performance status:   Not specified   Life expectancy:   Not specified   Hematopoietic:   WBC greater than 3,000/mm3   Platelet count greater than 100,000/mm3   Hepatic:   See Disease Characteristics   Bilirubin less than 2.0 mg/dL   ALT less than 1.5 times upper limit of normal OR AST less than 60 IU/L   Renal:   Creatinine less than 1.2 mg/dL   Other:   Not pregnant or lactating within the past 6 months   Fertile patients must use effective barrier contraception   No other prior or concurrent malignancy except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or ipsilateral in situ breast carcinoma   No psychiatric or addictive disorders that would preclude study   No non-malignant systemic disease that would preclude study   PRIOR CONCURRENT THERAPY:   Biologic therapy:   Prior trastuzumab (Herceptin) allowed   Chemotherapy:   See Disease Characteristics   No prior adjuvant or neoadjuvant chemotherapy for breast cancer   Endocrine therapy:   No prior endocrine therapy for breast cancer or prevention   No prior tamoxifen or raloxifene for breast cancer   Radiotherapy:   No prior radiotherapy for breast cancer except primary irradiation   Surgery:   See Disease Characteristics   Other:   No prior preventative therapy for breast cancer